Biotech
Biotech giant Genentech (DNA) received regulatory clearance in the U.S. for Lucentis, a drug designed to treat an eye disease that can progress until it ultimately leads to blindness.
Earlier in the day Friday, investors had already been expecting the approval and sent Genentech's shares up more than 3%. Recently, the stock rose $2.74, or 3.4%, to $82.87. Lucentis will be used against a condition called wet age-related macular degeneration. The drug has performed well in clinical trials showing its efficacy, including one that involved a head-to-head comparison with another treatment, Visudyne from Novartis' (NVS) and QLT (QLTI). During the trial, Lucentis actually improved the vision of some patients. While clinical trial results presented to the Food and Drug Administration to obtain marketing approval for a drug often compare the experimental product with a placebo, a direct comparison with an existing treatment is considered better evidence of its effectiveness, some researchers believe. Genentech expects to ship the drug immediately. When Lucentis becomes available, Visudyne won't be its only competition. Another option for treating AMD is Macugen, a drug sold by OSI Pharmaceuticals (OSIP). OSI inherited Macugen when it acquired Eyetech Pharmaceuticals last year.TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn MoreOptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn MoreReal Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn MoreStocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,419.86 | 1,313.32 | 2,837.36 | 16.25 |
Oil *
103.00
|
|
DOWN
160.83 |
DOWN
19.10 |
DOWN
33.63 |
DOWN
1.06 |
10 Yr
1.62%
SPDR Gold
151.91
|
|
-1.28%
|
-1.43%
|
-1.17%
|
-6.12%
|
Data delayed 20 minutes |


Connect with TheStreet